CA2512729C - Identification and engineering of antibodies with variant fc regions and methods of using same - Google Patents
Identification and engineering of antibodies with variant fc regions and methods of using same Download PDFInfo
- Publication number
- CA2512729C CA2512729C CA2512729A CA2512729A CA2512729C CA 2512729 C CA2512729 C CA 2512729C CA 2512729 A CA2512729 A CA 2512729A CA 2512729 A CA2512729 A CA 2512729A CA 2512729 C CA2512729 C CA 2512729C
- Authority
- CA
- Canada
- Prior art keywords
- region
- variant
- antigen
- wild
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 73
- 230000004048 modification Effects 0.000 claims abstract description 233
- 238000012986 modification Methods 0.000 claims abstract description 233
- 150000001413 amino acids Chemical class 0.000 claims abstract description 200
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 87
- 201000011510 cancer Diseases 0.000 claims abstract description 64
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims abstract description 52
- 238000006467 substitution reaction Methods 0.000 claims description 323
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 168
- 230000027455 binding Effects 0.000 claims description 112
- 239000000427 antigen Substances 0.000 claims description 72
- 102000036639 antigens Human genes 0.000 claims description 71
- 108091007433 antigens Proteins 0.000 claims description 71
- 210000004027 cell Anatomy 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 35
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical group OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 35
- 102000039446 nucleic acids Human genes 0.000 claims description 35
- 108020004707 nucleic acids Proteins 0.000 claims description 35
- 150000007523 nucleic acids Chemical class 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 15
- 230000001965 increasing effect Effects 0.000 claims description 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 9
- 101150029707 ERBB2 gene Proteins 0.000 claims description 9
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 9
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- -1 GAGE-2 Proteins 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- 238000011275 oncology therapy Methods 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 claims description 3
- 238000001794 hormone therapy Methods 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims 6
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 4
- 108010008707 Mucin-1 Proteins 0.000 claims 4
- 201000005296 lung carcinoma Diseases 0.000 claims 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 3
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 3
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 3
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 claims 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 3
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 3
- 108091008605 VEGF receptors Proteins 0.000 claims 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 150000002270 gangliosides Chemical class 0.000 claims 3
- 101150047061 tag-72 gene Proteins 0.000 claims 3
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 108010054404 Adenylyl-sulfate kinase Proteins 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 102000007269 CA-125 Antigen Human genes 0.000 claims 2
- 108010008629 CA-125 Antigen Proteins 0.000 claims 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 2
- 102100032912 CD44 antigen Human genes 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 2
- 101000798109 Homo sapiens Melanotransferrin Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims 2
- 102100032239 Melanotransferrin Human genes 0.000 claims 2
- 102100023123 Mucin-16 Human genes 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 2
- 102100039024 Sphingosine kinase 1 Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- CXQCLLQQYTUUKJ-ALWAHNIESA-N beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1<->1')-Cer(d18:1/18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 CXQCLLQQYTUUKJ-ALWAHNIESA-N 0.000 claims 2
- 210000001900 endoderm Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 2
- GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 claims 2
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 claims 2
- 235000020256 human milk Nutrition 0.000 claims 2
- 210000004251 human milk Anatomy 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 108010071421 milk fat globule Proteins 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims 1
- 101800000504 3C-like protease Proteins 0.000 claims 1
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 claims 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 102100039717 G antigen 1 Human genes 0.000 claims 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims 1
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 claims 1
- 101710123134 Ice-binding protein Proteins 0.000 claims 1
- 101710082837 Ice-structuring protein Proteins 0.000 claims 1
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 claims 1
- 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 102000046101 human AFP Human genes 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 101800000607 p15 Proteins 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 158
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 157
- 229920001184 polypeptide Polymers 0.000 abstract description 156
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 57
- 102000018358 immunoglobulin Human genes 0.000 abstract description 57
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 40
- 230000001225 therapeutic effect Effects 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 33
- 239000012636 effector Substances 0.000 abstract description 31
- 238000011282 treatment Methods 0.000 abstract description 31
- 201000010099 disease Diseases 0.000 abstract description 26
- 229940072221 immunoglobulins Drugs 0.000 abstract description 26
- 208000015181 infectious disease Diseases 0.000 abstract description 18
- 208000035473 Communicable disease Diseases 0.000 abstract description 17
- 230000001404 mediated effect Effects 0.000 abstract description 17
- 208000035475 disorder Diseases 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract description 10
- 230000003915 cell function Effects 0.000 abstract description 9
- 230000002708 enhancing effect Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 5
- 235000001014 amino acid Nutrition 0.000 description 187
- 229940024606 amino acid Drugs 0.000 description 186
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 153
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 133
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 96
- 235000013922 glutamic acid Nutrition 0.000 description 96
- 239000004220 glutamic acid Substances 0.000 description 96
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 81
- 235000009582 asparagine Nutrition 0.000 description 81
- 229960001230 asparagine Drugs 0.000 description 81
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 72
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 68
- 229960000310 isoleucine Drugs 0.000 description 68
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 67
- 235000004400 serine Nutrition 0.000 description 67
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 66
- 229930182817 methionine Natural products 0.000 description 62
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 61
- 235000003704 aspartic acid Nutrition 0.000 description 50
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 50
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 50
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 49
- 238000003556 assay Methods 0.000 description 47
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 44
- 239000004474 valine Substances 0.000 description 44
- 235000014393 valine Nutrition 0.000 description 44
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 38
- 238000012286 ELISA Assay Methods 0.000 description 36
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 29
- 125000000539 amino acid group Chemical group 0.000 description 28
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 27
- 239000004472 Lysine Substances 0.000 description 27
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 27
- 239000004473 Threonine Substances 0.000 description 27
- 235000004279 alanine Nutrition 0.000 description 26
- 230000006870 function Effects 0.000 description 25
- 102000005962 receptors Human genes 0.000 description 25
- 108020003175 receptors Proteins 0.000 description 25
- 238000002965 ELISA Methods 0.000 description 24
- 239000003795 chemical substances by application Substances 0.000 description 24
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 206010039073 rheumatoid arthritis Diseases 0.000 description 23
- 230000007423 decrease Effects 0.000 description 20
- 239000004475 Arginine Chemical group 0.000 description 19
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 19
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 19
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 19
- 230000035772 mutation Effects 0.000 description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 17
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 17
- 208000023275 Autoimmune disease Diseases 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 238000012217 deletion Methods 0.000 description 15
- 230000037430 deletion Effects 0.000 description 15
- 230000013595 glycosylation Effects 0.000 description 15
- 238000006206 glycosylation reaction Methods 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 230000003993 interaction Effects 0.000 description 14
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 14
- 230000000069 prophylactic effect Effects 0.000 description 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 13
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 13
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 12
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 206010057249 Phagocytosis Diseases 0.000 description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 11
- KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 11
- 230000003213 activating effect Effects 0.000 description 11
- 206010003246 arthritis Diseases 0.000 description 11
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 210000001503 joint Anatomy 0.000 description 11
- 230000008782 phagocytosis Effects 0.000 description 11
- 235000013930 proline Nutrition 0.000 description 11
- 238000012289 standard assay Methods 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 150000001720 carbohydrates Chemical group 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 108010087819 Fc receptors Proteins 0.000 description 8
- 102000009109 Fc receptors Human genes 0.000 description 8
- 108091006020 Fc-tagged proteins Proteins 0.000 description 8
- 206010042674 Swelling Diseases 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 238000000099 in vitro assay Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- 210000005253 yeast cell Anatomy 0.000 description 7
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 6
- 239000004471 Glycine Chemical group 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 6
- 230000002519 immonomodulatory effect Effects 0.000 description 6
- 239000012678 infectious agent Substances 0.000 description 6
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 5
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 238000002818 protein evolution Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 4
- 238000012926 crystallographic analysis Methods 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000012916 structural analysis Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 108091008042 inhibitory receptors Proteins 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 206010023230 Joint stiffness Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101100260768 Mus musculus Tlx1 gene Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000022244 formylation Effects 0.000 description 2
- 238000006170 formylation reaction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000014207 opsonization Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 102220632799 Immunoglobulin heavy variable 1-69_R11A_mutation Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000271569 Rhea Species 0.000 description 1
- 208000009921 Rheumatoid Nodule Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000036456 mitotic arrest Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 108700028325 pokeweed antiviral Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43949803P | 2003-01-09 | 2003-01-09 | |
| US60/439,498 | 2003-01-09 | ||
| US45604103P | 2003-03-19 | 2003-03-19 | |
| US60/456,041 | 2003-03-19 | ||
| US51454903P | 2003-10-23 | 2003-10-23 | |
| US60/514,549 | 2003-10-23 | ||
| PCT/US2004/000643 WO2004063351A2 (en) | 2003-01-09 | 2004-01-09 | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2512729A1 CA2512729A1 (en) | 2004-07-29 |
| CA2512729C true CA2512729C (en) | 2014-09-16 |
Family
ID=32719210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2512729A Expired - Lifetime CA2512729C (en) | 2003-01-09 | 2004-01-09 | Identification and engineering of antibodies with variant fc regions and methods of using same |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US7355008B2 (enExample) |
| EP (2) | EP1587540B1 (enExample) |
| JP (3) | JP2006524039A (enExample) |
| AU (1) | AU2004204494B2 (enExample) |
| CA (1) | CA2512729C (enExample) |
| ES (1) | ES2897506T3 (enExample) |
| IL (1) | IL169603A (enExample) |
| WO (1) | WO2004063351A2 (enExample) |
Families Citing this family (757)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| PL213948B1 (pl) * | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20080254027A1 (en) * | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| US8093357B2 (en) * | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
| ATE536188T1 (de) * | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
| US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8044180B2 (en) * | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8530627B2 (en) * | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8193318B2 (en) * | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8187593B2 (en) * | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| ES2897506T3 (es) * | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US20070275460A1 (en) * | 2003-03-03 | 2007-11-29 | Xencor.Inc. | Fc Variants With Optimized Fc Receptor Binding Properties |
| US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8388955B2 (en) * | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| JP5416338B2 (ja) * | 2003-05-09 | 2014-02-12 | デューク ユニバーシティ | Ｃｄ２０特異的抗体およびその使用方法 |
| EP2239271A1 (en) * | 2003-06-13 | 2010-10-13 | Biogen Idec MA Inc. | Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| GB0324368D0 (en) * | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| RS55723B1 (sr) | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| WO2005063815A2 (en) * | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| WO2005047327A2 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US20050142133A1 (en) * | 2003-12-03 | 2005-06-30 | Xencor, Inc. | Optimized proteins that target the epidermal growth factor receptor |
| WO2005077981A2 (en) * | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| PL1706424T3 (pl) * | 2004-01-12 | 2010-04-30 | Mentrik Biotech Llc | Warianty regionu Fc |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| WO2005115452A2 (en) * | 2004-04-16 | 2005-12-08 | Macrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
| JP2007536932A (ja) | 2004-05-10 | 2007-12-20 | マクロジェニクス，インコーポレーテッド | ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| BRPI0513798A (pt) | 2004-07-26 | 2008-05-13 | Biogen Idec Inc | anticorpos anti-cd154 |
| AU2005274905B2 (en) * | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| EP1784424A4 (en) * | 2004-08-16 | 2009-03-18 | Medimmune Inc | EPH RECEPTOR BINDING FC VARIANTS HAVING CELLULAR CELLULAR ACTIVITY DEPENDENT ANTIBODIES |
| US20060046961A1 (en) * | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
| WO2006031994A2 (en) * | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
| AU2005335714B2 (en) * | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CA2587617C (en) * | 2004-11-12 | 2011-02-01 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| EP1833849A4 (en) * | 2004-12-15 | 2009-08-05 | Macrogenics Inc | FC-GAMMA-RIIB-SPECIFIC ANTIBODIES AND METHODS FOR THEIR USE |
| DE602005026706D1 (de) * | 2004-12-30 | 2011-04-14 | Us Government | Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung |
| US20060275282A1 (en) * | 2005-01-12 | 2006-12-07 | Xencor, Inc. | Antibodies and Fc fusion proteins with altered immunogenicity |
| KR101569300B1 (ko) | 2005-02-07 | 2015-11-13 | 로슈 글리카트 아게 | Ｅｇｆｒ 에 결합하는 항원 결합 분자, 이를 코딩하는 벡터, 및 그의 용도 |
| KR101289537B1 (ko) | 2005-02-15 | 2013-07-31 | 듀크 유니버시티 | 항-ｃｄ19 항체 및 종양학에서 이의 용도 |
| DK2529619T3 (en) | 2005-02-17 | 2016-01-11 | Biogen Ma Inc | Treatment of neurological disorders |
| US20060223096A1 (en) * | 2005-03-25 | 2006-10-05 | Glycart Biotechnology Ag | Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function |
| WO2006105062A2 (en) * | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| EP1871808A2 (en) * | 2005-03-31 | 2008-01-02 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9296816B2 (en) | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| JP5315489B2 (ja) * | 2005-04-26 | 2013-10-16 | アール クレア アンド カンパニー | エフェクター機能が増強されたヒトＩｇＧ抗体を作製する方法 |
| EP1885755A4 (en) | 2005-05-05 | 2009-07-29 | Univ Duke | CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES |
| CN101212967A (zh) | 2005-05-10 | 2008-07-02 | 因塞特公司 | 吲哚胺2,3-双加氧酶调节剂及其用法 |
| WO2006122187A2 (en) | 2005-05-10 | 2006-11-16 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| SI2460831T1 (sl) | 2005-05-27 | 2017-01-31 | Biogen Ma Inc. | Protitelesa, ki se vežejo na TWEAK |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| WO2007005612A2 (en) * | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
| US7557190B2 (en) | 2005-07-08 | 2009-07-07 | Xencor, Inc. | Optimized proteins that target Ep-CAM |
| AU2006267090B2 (en) * | 2005-07-11 | 2013-03-07 | Provention Bio, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| SG164379A1 (en) | 2005-07-21 | 2010-09-29 | Genmab As | Potency assays for antibody drug substance binding to an fc receptor |
| ES2526811T3 (es) | 2005-08-10 | 2015-01-15 | Macrogenics, Inc. | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos |
| CN103204935B (zh) | 2005-08-26 | 2014-12-10 | 罗氏格黎卡特股份公司 | 具有改变的细胞信号传导活性的修饰的抗原结合分子 |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| JP4860703B2 (ja) | 2005-10-06 | 2012-01-25 | ゼンコー・インコーポレイテッド | 最適化された抗ｃｄ３０抗体 |
| KR20080073293A (ko) | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| CN101484470B (zh) * | 2005-10-21 | 2014-07-23 | 阿伊沃生物制剂有限公司 | 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途 |
| JP2009517339A (ja) * | 2005-11-01 | 2009-04-30 | ノバルティス アーゲー | 抗ｃｄ４０抗体の使用 |
| WO2007055916A2 (en) * | 2005-11-07 | 2007-05-18 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1960549A4 (en) * | 2005-11-30 | 2010-01-13 | Univ Southern California | FC POLYMORPHISMS FOR PREDICTING A DISEASE AND PROMOTING TREATMENT |
| FR2894982A1 (fr) * | 2005-12-16 | 2007-06-22 | Lab Francais Du Fractionnement | Procede de preparation d'anticorps selectifs des recepteurs fc activateurs |
| US20080071063A1 (en) * | 2006-02-03 | 2008-03-20 | Medimmune, Inc. | Protein Formulations |
| WO2007103469A2 (en) | 2006-03-06 | 2007-09-13 | Aeres Biomedical Ltd. | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP1999470A4 (en) * | 2006-03-10 | 2009-08-19 | Macrogenics Inc | IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF |
| CA2648849A1 (en) * | 2006-04-14 | 2007-10-25 | Trubion Pharmaceuticals, Inc. | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
| US20100080794A1 (en) * | 2006-04-14 | 2010-04-01 | Takashi Tsuji | Mutant polypeptide having effector function |
| EP2021029B1 (en) | 2006-05-26 | 2014-06-11 | MacroGenics, Inc. | Humanized fc gamma riib-specific antibodies and methods of use thereof |
| JP2009544761A (ja) * | 2006-06-14 | 2009-12-17 | マクロジェニクス，インコーポレーテッド | 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法 |
| LT2029173T (lt) * | 2006-06-26 | 2016-11-10 | Macrogenics, Inc. | Fc riib specifiniai antikūnai ir jų panaudojimo būdai |
| EP2032159B1 (en) * | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| WO2008008482A2 (en) * | 2006-07-13 | 2008-01-17 | Genentech, Inc. | Altered br3-binding polypeptides |
| SG173385A1 (en) | 2006-07-14 | 2011-08-29 | Ac Immune S A Ch | Humanized antibody against amyloid beta |
| AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
| AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
| CA2662340C (en) * | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| JPWO2008032833A1 (ja) * | 2006-09-14 | 2010-01-28 | 株式会社医学生物学研究所 | Ａｄｃｃ活性を増強させた抗体及びその製造方法 |
| US8394374B2 (en) * | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
| US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| US8652466B2 (en) * | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| AU2007337082A1 (en) * | 2006-12-21 | 2008-07-03 | Macrogenics Inc. | Methods for the treatment of LADA and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
| CA2675352A1 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
| EP2139924B1 (en) * | 2007-03-29 | 2016-07-06 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| DK2155789T3 (da) | 2007-05-01 | 2013-10-21 | Res Dev Foundation | Immunoglobulin-Fc-biblioteker |
| EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US20100291073A1 (en) | 2007-05-14 | 2010-11-18 | Medimmune, Llc | Methods of reducing eosinophil levels |
| US20090155249A1 (en) * | 2007-06-12 | 2009-06-18 | Ac Immune S.A. | Humanized antibody igg1 |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US7580304B2 (en) * | 2007-06-15 | 2009-08-25 | United Memories, Inc. | Multiple bus charge sharing |
| AU2008265984B2 (en) | 2007-06-21 | 2014-07-17 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US20110077383A1 (en) * | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
| CA2694488A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| PE20120259A1 (es) | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| NZ585110A (en) * | 2007-10-05 | 2012-09-28 | Genentech Inc | Method and compositions for diagnosis and treatment of amyloidosis |
| PL2238166T3 (pl) | 2007-10-05 | 2014-07-31 | Genentech Inc | Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu |
| EP2650308A3 (en) * | 2007-10-05 | 2014-11-12 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| JP5427348B2 (ja) * | 2007-10-12 | 2014-02-26 | 株式会社医学生物学研究所 | エフェクター機能が向上した抗体 |
| EP2201098B1 (en) * | 2007-10-18 | 2013-08-28 | Unilever PLC | Method for producing a foaming agent |
| US20120047586A9 (en) * | 2007-10-24 | 2012-02-23 | Otsuka Chemical Co., Ltd | Polypeptide having enhanced effector function |
| US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
| US8795667B2 (en) * | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
| CA2708871C (en) | 2007-12-21 | 2017-11-21 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173 |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| DK2808343T3 (da) | 2007-12-26 | 2019-08-19 | Xencor Inc | Fc-varianter med ændret binding til FcRn |
| CN102083460A (zh) | 2008-01-18 | 2011-06-01 | 米迪缪尼有限公司 | 用于位点特异性偶联的半胱氨酸工程化抗体 |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| US20110091904A1 (en) * | 2008-03-05 | 2011-04-21 | Gyros Patent Ab | Method for determination of affinity and kinetic constants |
| US20100112139A1 (en) * | 2008-03-28 | 2010-05-06 | Conopco, Inc., D/B/A Unilever | Foaming Agents Comprising Hydrophobin |
| MX2010010387A (es) | 2008-04-02 | 2010-10-15 | Macrogenics Inc | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. |
| CA2720368C (en) * | 2008-04-02 | 2017-08-22 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
| US20110081347A1 (en) * | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
| AR072160A1 (es) | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| WO2009155257A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| WO2010011439A2 (en) | 2008-06-17 | 2010-01-28 | Indiana University Research And Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
| CN104042611B (zh) | 2008-07-08 | 2019-05-14 | 因塞特控股公司 | 作为吲哚胺2，3-双加氧酶的抑制剂的1，2，5-噁二唑 |
| ES2442024T3 (es) | 2008-07-15 | 2014-02-07 | Academia Sinica | Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados |
| CN102264763B (zh) | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | 定向于dll4的抗体及其用途 |
| PL2352521T3 (pl) * | 2008-10-14 | 2021-03-08 | Genentech, Inc. | Warianty immunoglobuliny i ich zastosowania |
| BRPI0919788A2 (pt) * | 2008-10-16 | 2016-09-06 | Unilever Nv | solução aquosa de hidrofobina contendo antiespumante |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| MX2011006416A (es) | 2008-12-19 | 2011-07-12 | Macrogenics Inc | Diacuerpos covalentes y sus usos. |
| WO2010080609A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| TW201029662A (en) | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
| AU2009331528A1 (en) | 2008-12-23 | 2011-08-11 | Astrazeneca Ab | Targeted binding agents directed to alpha5beta1 and uses thereof |
| EP2382238A1 (en) | 2008-12-31 | 2011-11-02 | Biogen Idec MA Inc. | Anti-lymphotoxin antibodies |
| WO2010096394A2 (en) * | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| CN102448482A (zh) | 2009-03-27 | 2012-05-09 | 范安德尔研究所 | 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法 |
| SG174963A1 (en) | 2009-03-31 | 2011-11-28 | Roche Glycart Ag | Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan |
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| CA2704702C (en) * | 2009-06-02 | 2018-06-12 | Unilever Plc | Aerated baked products |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| WO2011005481A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
| JP5683581B2 (ja) * | 2009-06-30 | 2015-03-11 | リサーチ ディベロップメント ファウンデーション | 免疫グロブリンＦｃポリペプチド |
| CA2766409C (en) | 2009-07-03 | 2023-04-25 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
| JP2013502458A (ja) | 2009-08-24 | 2013-01-24 | アムニクス オペレーティング インコーポレイテッド | 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法 |
| MX339608B (es) | 2009-08-31 | 2016-05-31 | Roche Glycart Ag | Anticuerpos del antigeno carcinoembrionario (cea). |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| JP6091894B2 (ja) | 2009-09-16 | 2017-03-15 | ジェネンテック， インコーポレイテッド | コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用 |
| BR112012007760A2 (pt) | 2009-10-07 | 2015-08-25 | Macrogenics Inc | Método de atenuar fucosilação pós translacional de uma região fc de igc humana, anticorpo que se liga especificamente a um antigeno de câncer caracteristico de um cancêr polipeptideo |
| SMT201700248T1 (it) | 2009-11-02 | 2017-07-18 | Univ Washington | Composizioni terapeutiche di nucleasi e metodi |
| MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| AU2010336029B2 (en) | 2009-12-23 | 2011-10-13 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
| US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
| US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
| MA34004B1 (fr) | 2010-01-28 | 2013-02-01 | Glaxo Group Ltd | Protéines de liaison à cd127 |
| AU2011214440A1 (en) | 2010-02-09 | 2012-08-30 | Glaxo Group Limited | Treatment of a metabolic disorder |
| TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| ES2602971T3 (es) | 2010-03-02 | 2017-02-23 | Kyowa Hakko Kirin Co., Ltd. | Composición de anticuerpo modificado |
| UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
| EP2982380B1 (en) | 2010-03-04 | 2021-09-01 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| ES2575160T3 (es) | 2010-03-15 | 2016-06-24 | The Board Of Trustees Of The University Of Illinois | Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G |
| AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
| JP2013523098A (ja) | 2010-03-29 | 2013-06-17 | ザイムワークス，インコーポレイテッド | 強化又は抑制されたエフェクター機能を有する抗体 |
| WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| JP6121323B2 (ja) | 2010-05-13 | 2017-05-10 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
| TW201210612A (en) | 2010-06-03 | 2012-03-16 | Glaxo Group Ltd | Humanised antigen binding proteins |
| AU2011268327B2 (en) | 2010-06-16 | 2016-02-25 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
| RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
| CA2803164C (en) | 2010-06-24 | 2018-08-21 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| EA201291482A1 (ru) | 2010-07-09 | 2013-10-30 | Байоджен Айдек Хемофилия Инк. | Химерные факторы коагуляции |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| JP5972871B2 (ja) | 2010-07-20 | 2016-08-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｉｌ−２３ヘテロ二量体特異的抗体 |
| MX349662B (es) | 2010-07-22 | 2017-08-08 | Univ California | Anticuerpos de antigenos antitumorales y metodos de uso. |
| MX341369B (es) | 2010-07-30 | 2016-08-17 | Genentech Inc * | Anticuerpo anti-beta-amiloide humanizado seguro y funcional. |
| EP2601216B1 (en) | 2010-08-02 | 2018-01-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| JP5841149B2 (ja) | 2010-08-13 | 2016-01-13 | ロシュ グリクアート アーゲー | 抗テネイシンｃａ２抗体及び使用の方法 |
| NO2603530T3 (enExample) | 2010-08-13 | 2018-04-07 | ||
| JP2013537416A (ja) | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法 |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| SG188324A1 (en) | 2010-09-03 | 2013-04-30 | Academia Sinica | Anti-c-met antibody and methods of use thereof |
| WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
| RU2013115927A (ru) | 2010-09-10 | 2014-10-20 | Апексиджен, Инк. | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ |
| KR101912957B1 (ko) | 2010-09-27 | 2018-10-29 | 모르포시스 아게 | 다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉 |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| EP4231014A3 (en) | 2010-11-30 | 2024-08-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| TR201815863T4 (tr) | 2010-11-30 | 2018-11-21 | Chugai Pharmaceutical Co Ltd | Sitotoksisiteyi indükleyen terapötik madde. |
| US9029502B2 (en) | 2010-12-20 | 2015-05-12 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| PE20140186A1 (es) | 2010-12-22 | 2014-02-13 | Univ Indiana Res & Tech Corp | Analogos de glucagon que presentan actividad de receptor de gip |
| EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| EP2663647A4 (en) | 2011-01-14 | 2015-08-19 | Redwood Bioscience Inc | POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD |
| US20120258073A1 (en) | 2011-02-10 | 2012-10-11 | Christian Gerdes | Immunotherapy |
| WO2012116927A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
| MX341921B (es) | 2011-02-28 | 2016-09-07 | Hoffmann La Roche | Proteinas de union a antigeno. |
| RS56793B1 (sr) | 2011-03-02 | 2018-04-30 | Roche Glycart Ag | Cea antitela |
| BR112013021863A2 (pt) | 2011-03-03 | 2016-11-22 | Apexigen Inc | anticorpos anti-receptor il-6 e métodos de uso |
| AU2012225246B2 (en) | 2011-03-10 | 2016-01-21 | Omeros Corporation | Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
| CA2830254C (en) * | 2011-03-16 | 2019-09-10 | Amgen Inc. | Fc variants |
| EP3590965A1 (en) | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
| SI2697257T1 (sl) | 2011-04-13 | 2017-02-28 | Bristol-Myers Squibb Company | FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve |
| PT2699264T (pt) | 2011-04-20 | 2018-05-23 | Medimmune Llc | Anticorpos e outras moléculas que ligam b7-h1 e pd-1 |
| AU2012245205B2 (en) | 2011-04-21 | 2017-06-01 | The Regents Of The University Of California, A California Corporation | Compositions and methods for the treatment of neuromyelitis optica |
| RU2632647C2 (ru) | 2011-04-22 | 2017-10-06 | Аптево Рисерч Энд Девелопмент Ллс | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы |
| SI2704737T1 (en) | 2011-04-29 | 2018-06-29 | University Of Washington | Therapeutic nuclease compositions and methods |
| SG194701A1 (en) | 2011-04-29 | 2013-12-30 | Apexigen Inc | Anti-cd40 antibodies and methods of use |
| CN107722124A (zh) | 2011-05-21 | 2018-02-23 | 宏观基因有限公司 | 能够与人和非人cd3结合的cd3结合分子 |
| ES2605784T3 (es) | 2011-05-21 | 2017-03-16 | Macrogenics, Inc. | Dominios de enlazamiento a suero desinmunizados y su uso para extender la vida media en suero |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| EP3527218A1 (en) | 2011-06-10 | 2019-08-21 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
| JP6179864B2 (ja) | 2011-06-22 | 2017-08-16 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト |
| CN103827300A (zh) | 2011-06-30 | 2014-05-28 | 中外制药株式会社 | 异源二聚化多肽 |
| US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
| AU2012295394B2 (en) | 2011-08-12 | 2016-04-14 | Omeros Corporation | Anti-FZD10 monoclonal antibodies and methods for their use |
| EP2756094B1 (en) | 2011-08-15 | 2017-12-27 | Medlmmune, LLC | Anti-b7-h4 antibodies and their uses |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| JP2014531210A (ja) | 2011-09-30 | 2014-11-27 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | ＴＬ１ａに対する抗体およびその使用 |
| ES2757473T3 (es) | 2011-09-30 | 2020-04-29 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA) |
| RU2014122184A (ru) | 2011-11-02 | 2015-12-10 | Апексиджен, Инк. | Антитела к kdr и способы их применения |
| CA2854806A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| EP2780031B1 (en) | 2011-11-17 | 2018-03-07 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| EP3712173B1 (en) | 2011-12-05 | 2023-07-12 | X-Body, Inc. | Pdgf receptor beta binding polypeptides |
| ES2816078T3 (es) | 2011-12-20 | 2021-03-31 | Medimmune Llc | Polipéptidos modificados para armazones de anticuerpo biespecífico |
| US9573987B2 (en) | 2011-12-20 | 2017-02-21 | Indiana University Research And Technology Corporation | CTP-based insulin analogs for treatment of diabetes |
| CA3111357A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| KR102212098B1 (ko) | 2012-01-12 | 2021-02-03 | 바이오버라티브 테라퓨틱스 인크. | 키메라 인자 viii 폴리펩티드들과 이의 용도 |
| US10577416B2 (en) | 2012-02-07 | 2020-03-03 | Innate Pharma, S.A. | Mica binding agents |
| CN113480639A (zh) | 2012-02-09 | 2021-10-08 | 中外制药株式会社 | 抗体的Fc区变异体 |
| RU2644341C2 (ru) | 2012-02-10 | 2018-02-08 | Дженентек, Инк. | Одноцепочечные антитела и другие гетеромультимеры |
| MX369862B (es) | 2012-02-15 | 2019-11-25 | Bioverativ Therapeutics Inc | Composiciones del factor viii y metodos para hacerlas y usarlas. |
| JP6383666B2 (ja) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | 組換え第ｖｉｉｉ因子タンパク質 |
| EP3246339B1 (en) | 2012-03-28 | 2019-10-09 | Sanofi | Antibodies to bradykinin b1 receptor ligands |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| HK1207654A1 (en) | 2012-04-27 | 2016-02-05 | Bioatla, Llc | Modified antibody regions and uses thereof |
| WO2013169657A1 (en) | 2012-05-07 | 2013-11-14 | Sanofi | Methods for preventing biofilm formation |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
| CN107964042B (zh) * | 2012-05-30 | 2022-04-19 | 中外制药株式会社 | 靶组织特异性抗原结合分子 |
| JP2015525222A (ja) | 2012-06-08 | 2015-09-03 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | キメラ性凝固因子 |
| EP4079316A1 (en) | 2012-06-08 | 2022-10-26 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
| EP2862875B1 (en) | 2012-06-14 | 2023-09-06 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION |
| EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| TW201402611A (zh) | 2012-06-21 | 2014-01-16 | Univ Indiana Res & Tech Corp | 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物 |
| KR20150039748A (ko) | 2012-06-21 | 2015-04-13 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체 활성을 나타내는 글루카곤의 유사체들 |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| CA2871880A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| RU2015100656A (ru) | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения |
| US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
| EA201792485A3 (ru) | 2012-07-11 | 2019-03-29 | Амуникс Оперэйтинг Инк. | Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты) |
| US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
| DK2877493T3 (en) | 2012-07-25 | 2018-06-14 | Celldex Therapeutics Inc | ANTI-KIT ANTIBODIES AND APPLICATIONS THEREOF |
| PL2880170T3 (pl) | 2012-08-02 | 2017-02-28 | F.Hoffmann-La Roche Ag | SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA |
| AR092044A1 (es) | 2012-08-07 | 2015-03-18 | Roche Glycart Ag | Inmunoterapia mejorada |
| US9914956B2 (en) | 2012-08-18 | 2018-03-13 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| SG10201701831VA (en) | 2012-09-12 | 2017-05-30 | Genzyme Corp | Fc containing polypeptides with altered glycosylation and reduced effector function |
| US20150239977A1 (en) * | 2012-09-27 | 2015-08-27 | Massachusetts Institute Of Technology | Cd20- and egfr-binding proteins with enhanced stability |
| KR102270618B1 (ko) | 2012-10-30 | 2021-06-30 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| BR112015010740B1 (pt) | 2012-11-13 | 2024-01-30 | Biontech Ag | Agentes para tratamento de doenças cancerosas expressando claudina |
| SMT201900242T1 (it) | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| WO2014093396A1 (en) | 2012-12-10 | 2014-06-19 | Biogen Idec Ma Inc. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
| AU2013361231A1 (en) | 2012-12-19 | 2015-06-04 | Amplimmune, Inc. | B7-H4 specific antibodies, and compositions and methods of use thereof |
| MX2015008117A (es) | 2012-12-21 | 2016-03-31 | Amplimmune Inc | Anticuerpos anti-h7cr. |
| KR102249779B1 (ko) | 2012-12-27 | 2021-05-07 | 추가이 세이야쿠 가부시키가이샤 | 헤테로이량화 폴리펩티드 |
| US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| WO2014117220A1 (en) | 2013-02-01 | 2014-08-07 | Transbio Ltd | Anti-cd83 antibodies and use thereof |
| ES2813501T3 (es) | 2013-02-12 | 2021-03-24 | Bristol Myers Squibb Co | Métodos de replegado de proteínas basados en filtración de flujo tangencial |
| EP3617220B1 (en) | 2013-02-12 | 2021-03-24 | Bristol-Myers Squibb Company | High ph protein refolding methods |
| KR20160002713A (ko) | 2013-02-13 | 2016-01-08 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도 |
| CN105263319A (zh) | 2013-02-13 | 2016-01-20 | 法国化学与生物科技实验室 | 具有经修饰的糖基化的蛋白及其生产方法 |
| EP2956482B1 (en) | 2013-02-14 | 2017-06-28 | Innate Pharma | Treatment of peripheral t cell lymphoma |
| PL2956477T5 (pl) | 2013-02-15 | 2024-05-27 | Bioverativ Therapeutics Inc. | Zoptymalizowany gen czynnika viii |
| EP3521312B1 (en) | 2013-02-20 | 2021-04-07 | Innate Pharma | A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| WO2014164534A2 (en) | 2013-03-11 | 2014-10-09 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
| EP3839044A1 (en) | 2013-03-14 | 2021-06-23 | MacroGenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
| WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| EA201890895A1 (ru) | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | Мультивалентные и моновалентные мультиспецифические комплексы и их применение |
| FR3003171B1 (fr) * | 2013-03-15 | 2015-04-10 | Lab Francais Du Fractionnement | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
| SG10201707600XA (en) | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| US10035859B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
| CA2903546A1 (en) | 2013-03-15 | 2014-09-25 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
| CN105142668B (zh) | 2013-03-15 | 2018-04-27 | 达纳-法伯癌症研究院公司 | 治疗性肽 |
| KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| CN105246914B (zh) | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
| CN106414489A (zh) | 2013-05-24 | 2017-02-15 | 米迪缪尼有限公司 | 抗-b7-h5抗体及其用途 |
| WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| JP6567506B2 (ja) * | 2013-05-31 | 2019-08-28 | ザイムワークス，インコーポレイテッド | 低下した又はサイレント化したエフェクター機能を持つヘテロ多量体 |
| WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
| US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
| JP6673200B2 (ja) | 2013-07-05 | 2020-03-25 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 骨髄異形成症候群（ｍｄｓ）を治療するための可溶性ｃｄ３３ |
| EP3875106A1 (en) | 2013-08-08 | 2021-09-08 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
| AU2014303375B2 (en) | 2013-08-09 | 2019-07-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
| UA116479C2 (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| SG10201710013RA (en) | 2013-08-13 | 2018-01-30 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
| TW201722994A (zh) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途 |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| DK3036320T4 (da) | 2013-08-19 | 2024-05-06 | Biogen Ma Inc | Styring af proteinglycosylering ved hjælp af dyrkningsmedietilsætning og cellekulturprocesparametre |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| EP3041484B1 (en) | 2013-09-06 | 2021-03-03 | Academia Sinica | Human inkt cell activation using glycolipids with altered glycosyl groups |
| US9481729B2 (en) | 2013-09-11 | 2016-11-01 | The University Of Hong Kong | Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| EP3903599A1 (en) | 2013-09-25 | 2021-11-03 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| DK3052192T3 (da) | 2013-10-02 | 2020-09-28 | Medimmune Llc | Neutraliserende anti-influenza a-antistoffer og anvendelser deraf |
| KR20160044060A (ko) | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 다중특이적 도메인 교환된 통상의 가변 경쇄 항체 |
| EP3929301A1 (en) * | 2013-10-14 | 2021-12-29 | SynAffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| WO2015057939A1 (en) | 2013-10-18 | 2015-04-23 | Biogen Idec Ma Inc. | Anti-s1p4 antibodies and uses thereof |
| PL3063275T3 (pl) | 2013-10-31 | 2020-03-31 | Resolve Therapeutics, Llc | Terapeutyczne fuzje nukleaza-albumina i sposoby |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| WO2015074063A1 (en) * | 2013-11-18 | 2015-05-21 | University Of Maryland, Baltimore | Hyper-glycosylated antibodies with selective fc receptor binding |
| AU2014354588B2 (en) | 2013-11-28 | 2020-07-02 | B-Creative Sweden Ab | Method of treating nephropathy |
| EP3763813A1 (en) | 2013-12-04 | 2021-01-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
| CA2932767A1 (en) | 2013-12-06 | 2015-06-11 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| CA2932465C (en) | 2013-12-18 | 2023-08-22 | Csl Limited | Methods of treating wounds in a diabetic subject |
| US10137170B2 (en) | 2013-12-20 | 2018-11-27 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides |
| EP3083933A1 (en) | 2013-12-20 | 2016-10-26 | Biogen MA Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
| AU2014369999B2 (en) | 2013-12-24 | 2019-12-12 | The Board Of Regents Of The University Of Texas System | FcRn antagonists and methods of use |
| MY204756A (en) | 2014-01-10 | 2024-09-11 | Bioverativ Therapeutics Inc | Factor viii chimeric proteins and uses thereof |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| JP2017507118A (ja) | 2014-01-16 | 2017-03-16 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | がんの処置および検出のための組成物および方法 |
| WO2015112597A1 (en) * | 2014-01-21 | 2015-07-30 | Belmont Biosciences, Inc. | Variants of igg fc with limited amine groups that retain functional properties |
| AU2015217278B2 (en) | 2014-02-14 | 2020-03-19 | Macrogenics, Inc. | Improved methods for the treatment of vascularizing cancers |
| WO2015136052A1 (en) | 2014-03-14 | 2015-09-17 | Innate Pharma | Humanized antibodies with increased stability |
| AU2015229009B2 (en) | 2014-03-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring NKG2D pathway function against cancers |
| RS64072B1 (sr) | 2014-03-19 | 2023-04-28 | Genzyme Corp | Mesto-specifični glikoinženjering ciljnih delova |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| CN106164094B (zh) | 2014-03-21 | 2021-05-14 | X博迪公司 | 双特异性抗原结合多肽 |
| US11124760B2 (en) | 2014-03-24 | 2021-09-21 | Biogen Ma Inc. | Methods for overcoming glutamine deprivation during mammalian cell culture |
| TWI687428B (zh) | 2014-03-27 | 2020-03-11 | 中央研究院 | 反應性標記化合物及其用途 |
| EP3149036A4 (en) | 2014-05-27 | 2017-12-27 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| CA2950423A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| KR102512592B1 (ko) | 2014-05-27 | 2023-03-21 | 아카데미아 시니카 | 항-ｈｅｒ2 글리코항체 및 이의 용도 |
| AU2015267044A1 (en) | 2014-05-28 | 2016-12-15 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
| RU2718692C2 (ru) | 2014-05-29 | 2020-04-13 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения |
| PT3151921T (pt) | 2014-06-06 | 2019-11-21 | Bristol Myers Squibb Co | Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos |
| JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| AU2015279321B2 (en) | 2014-06-27 | 2021-03-04 | Innate Pharma, S.A. | Multispecific antigen binding proteins |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| WO2016014725A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
| BR122020025583B1 (pt) | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão |
| US9764122B2 (en) | 2014-07-25 | 2017-09-19 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having an occluding member |
| US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
| US10435470B2 (en) | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| WO2016030488A1 (en) | 2014-08-27 | 2016-03-03 | Innate Pharma | Treatment of celiac disease |
| FR3025515B1 (fr) | 2014-09-05 | 2016-09-09 | Lab Francais Du Fractionnement | Procede de purification d'un anticorps monoclonal |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
| KR20170062490A (ko) | 2014-09-26 | 2017-06-07 | 바이엘 파마 악티엔게젤샤프트 | 안정화된 아드레노메둘린 유도체 및 그의 용도 |
| US10717778B2 (en) | 2014-09-29 | 2020-07-21 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
| PL3204425T3 (pl) | 2014-10-09 | 2021-03-08 | Genzyme Corporation | Glikomodyfikowane koniugaty przeciwciał z lekami |
| PL3207130T3 (pl) | 2014-10-14 | 2020-02-28 | Halozyme, Inc. | Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania |
| WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| MA41685A (fr) | 2014-10-17 | 2017-08-22 | Biogen Ma Inc | Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère |
| AU2015336931B2 (en) | 2014-10-23 | 2021-04-29 | Kira Biotech Pty Limited | CD83 binding proteins and uses thereof |
| JP6889660B2 (ja) | 2014-10-23 | 2021-06-18 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 抗ｎｋｇ２ａ剤を用いた癌の処置 |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
| LT3699198T (lt) | 2014-11-17 | 2025-05-12 | Regeneron Pharmaceuticals, Inc. | Būdai navikams gydyti naudojant cd3×cd20 bispecifinį antikūną |
| ES2807182T3 (es) | 2014-11-21 | 2021-02-22 | Bristol Myers Squibb Co | Anticuerpos frente a CD73 y sus usos |
| WO2016081746A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| EP3220900B1 (en) | 2014-11-21 | 2020-09-23 | University of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
| EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| KR102691114B1 (ko) | 2015-01-24 | 2024-08-01 | 아카데미아 시니카 | 신규한 글리칸 콘주게이트 및 이를 사용하는 방법 |
| WO2016123143A1 (en) | 2015-01-26 | 2016-08-04 | The University Of Chicago | CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2 |
| CN107683289B (zh) | 2015-01-26 | 2021-08-06 | 芝加哥大学 | IL13Rα2结合剂和其在癌症治疗中的用途 |
| WO2016123591A2 (en) * | 2015-01-30 | 2016-08-04 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| WO2016130516A1 (en) | 2015-02-09 | 2016-08-18 | Research Development Foundation | Engineered immunoglobulin fc polypeptides displaying improved complement activation |
| AU2016230827B2 (en) | 2015-03-09 | 2021-10-28 | argenx BV | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
| WO2016149698A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies) |
| WO2016149710A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
| WO2016149695A1 (en) | 2015-03-19 | 2016-09-22 | Duke University | HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES) |
| EP3271022A4 (en) | 2015-03-19 | 2018-10-31 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
| EP3277725B1 (en) | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| FR3034420A1 (fr) | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
| AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
| FR3035879B1 (fr) * | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
| RS63897B1 (sr) | 2015-05-29 | 2023-02-28 | Bristol Myers Squibb Co | Antitela protiv ox40 i njihova primena |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| TWI870335B (zh) | 2015-06-12 | 2025-01-21 | 美商宏觀基因股份有限公司 | 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用 |
| EP3313876B1 (en) | 2015-06-23 | 2025-01-22 | Innate Pharma | Multispecific antigen binding proteins |
| AU2016284871B2 (en) | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| US10906971B2 (en) | 2015-06-26 | 2021-02-02 | Sanofi Biotechnology SAS | Monoclonal anti-IL-1RAcP antibodies |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| ES2898958T3 (es) | 2015-07-30 | 2022-03-09 | Macrogenics Inc | Moléculas de unión a PD-1 y LAG-3 y métodos de uso de las mismas |
| IL257231B (en) | 2015-08-03 | 2022-09-01 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same |
| WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
| EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | CD3-BINDING POLYPEPTIDES |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| EP3359192A4 (en) | 2015-10-08 | 2019-05-01 | MacroGenics, Inc. | COMBINATION THERAPY FOR CANCER TREATMENT |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| BR112018010172A2 (pt) | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
| EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| ES2901794T3 (es) | 2015-12-09 | 2022-03-23 | Hoffmann La Roche | Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco |
| MA44082A (fr) | 2015-12-14 | 2018-10-24 | Macrogenics Inc | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
| RS63548B1 (sr) | 2016-02-01 | 2022-09-30 | Bioverativ Therapeutics Inc | Optimizovani geni faktora viii |
| EP3423491A1 (en) | 2016-03-01 | 2019-01-09 | H. Hoffnabb-La Roche Ag | Obinutuzumab variants having altered cell death induction |
| SG10201913033UA (en) | 2016-03-04 | 2020-03-30 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| TW201808978A (zh) | 2016-03-08 | 2018-03-16 | 中央研究院 | N-聚醣及其陣列之模組化合成方法 |
| CN108779178A (zh) | 2016-03-15 | 2018-11-09 | 依奈特制药公司 | 抗mica抗体 |
| KR20180127407A (ko) | 2016-03-16 | 2018-11-28 | 메리맥 파마슈티컬즈, 인크. | 암 요법용 조작된 trail |
| WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| KR102744951B1 (ko) | 2016-03-28 | 2024-12-23 | 인사이트 코포레이션 | Tam 억제제로서 피롤로트리아진 화합물 |
| PE20190353A1 (es) | 2016-04-15 | 2019-03-07 | Macrogenics Inc | Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos |
| US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| WO2017196663A1 (en) | 2016-05-09 | 2017-11-16 | Bristol-Myers Squibb Company | Tl1a antibodies and uses thereof |
| CN109071640B (zh) | 2016-05-11 | 2022-10-18 | 豪夫迈·罗氏有限公司 | 经修饰抗生腱蛋白抗体及使用方法 |
| BR112018073660A2 (pt) | 2016-05-16 | 2019-02-19 | Baxalta Incorporated | anticorpos anti-fator ix pádua |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| AU2018276419A1 (en) | 2016-06-02 | 2019-10-17 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer |
| US10549081B2 (en) | 2016-06-23 | 2020-02-04 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
| CN119120423A (zh) | 2016-07-01 | 2024-12-13 | 分解治疗有限责任公司 | 优化的二核酸酶融合体和方法 |
| AU2017293423B2 (en) | 2016-07-05 | 2023-05-25 | Beone Medicines I Gmbh | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| EP4512829A3 (en) | 2016-07-14 | 2025-06-11 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| EP3487521A4 (en) | 2016-07-21 | 2020-07-01 | Emory University | ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM |
| US20190330318A1 (en) | 2016-07-25 | 2019-10-31 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
| US11858980B2 (en) | 2016-08-02 | 2024-01-02 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| AU2017306709A1 (en) | 2016-08-05 | 2019-03-14 | Humabs, BioMed SA | Anti-o2 antibodies and uses thereof |
| US10669344B2 (en) | 2016-08-12 | 2020-06-02 | Janssen Biotech, Inc. | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions |
| AU2017313085B2 (en) | 2016-08-19 | 2024-06-20 | Beone Medicines I Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
| US10538592B2 (en) | 2016-08-22 | 2020-01-21 | Cho Pharma, Inc. | Antibodies, binding fragments, and methods of use |
| US10981976B2 (en) | 2016-08-31 | 2021-04-20 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof |
| EP4360714A3 (en) | 2016-09-21 | 2024-07-24 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
| JP7069177B2 (ja) | 2016-09-21 | 2022-05-17 | ネクストキュア インコーポレイテッド | シグレック－１５に対する抗体及びその使用方法 |
| MX392374B (es) | 2016-09-28 | 2025-03-24 | Cohbar Inc | Peptidos terapeuticos relacionados con mots-c. |
| MA46534A (fr) | 2016-10-14 | 2019-08-21 | Xencor Inc | Protéines de fusion fc hétérodimères il15/il15r |
| SG11201903063UA (en) | 2016-10-19 | 2019-05-30 | Medimmune Llc | Anti-o1 antibodies and uses thereof |
| CN109863175A (zh) | 2016-10-21 | 2019-06-07 | 依奈特制药公司 | 用抗-kir3dl2药剂进行的治疗 |
| JP7206590B2 (ja) | 2016-10-28 | 2023-01-18 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| US11249082B2 (en) | 2016-10-29 | 2022-02-15 | University Of Miami | Zika virus assay systems |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
| AU2017363309A1 (en) | 2016-11-23 | 2019-07-11 | Bioverativ Therapeutics Inc. | Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X |
| CA3044838A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| CN110520150A (zh) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | 使用嵌合凝血因子治疗血友病性关节病的方法 |
| WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
| US20190322767A1 (en) | 2016-12-23 | 2019-10-24 | Innate Pharma | Heterodimeric antigen binding proteins |
| WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| US11357841B2 (en) | 2017-01-06 | 2022-06-14 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| EP3565888A1 (en) | 2017-01-06 | 2019-11-13 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
| US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| EP3583124A1 (en) | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| HUE060983T2 (hu) | 2017-02-17 | 2023-05-28 | Denali Therapeutics Inc | Mesterségesen elõállított transferrin receptort kötõ polipeptidek |
| US11117930B2 (en) | 2017-02-23 | 2021-09-14 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
| US12054544B2 (en) | 2017-02-24 | 2024-08-06 | Chugai Seiyaku Kabushiki Kaisha | Compositions comprising antigen-binding molecules |
| MX2019010028A (es) | 2017-02-28 | 2019-10-14 | Seattle Genetics Inc | Anticuerpos con cisteina mutada por conjugacion. |
| CN113480654B (zh) | 2017-03-28 | 2022-06-10 | 礼进生物医药科技（上海）有限公司 | 用于增强肿瘤微环境中免疫应答的治疗剂和方法 |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| JP6886854B2 (ja) * | 2017-04-13 | 2021-06-16 | シスメックス株式会社 | 被検物質の情報取得方法 |
| US20230140818A1 (en) | 2017-04-27 | 2023-05-04 | The University Of Hong Kong | Use of hcn inhibitors for treatment of cancer |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| WO2018209115A1 (en) | 2017-05-10 | 2018-11-15 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| WO2018213097A1 (en) | 2017-05-15 | 2018-11-22 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
| EP3630833A1 (en) | 2017-05-25 | 2020-04-08 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| JP2020523035A (ja) | 2017-06-07 | 2020-08-06 | エーディーアールエックス， インコーポレイテッド | タウ凝集阻害剤 |
| CN110799543A (zh) | 2017-06-26 | 2020-02-14 | 百济神州有限公司 | 肝细胞癌的免疫治疗 |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| WO2019011918A1 (en) | 2017-07-10 | 2019-01-17 | International - Drug - Development - Biotech | TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS |
| KR20250040746A (ko) | 2017-08-09 | 2025-03-24 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 이의 용도 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| AU2018318319A1 (en) | 2017-08-18 | 2020-02-20 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| EP3672986A1 (en) | 2017-08-22 | 2020-07-01 | Sanabio, LLC | Soluble interferon receptors and uses thereof |
| US11021540B2 (en) | 2017-09-07 | 2021-06-01 | Augusta University Research Institute, Inc. | Antibodies to programmed cell death protein 1 |
| AU2018342471B2 (en) | 2017-09-27 | 2023-08-24 | Incyte Corporation | Salts of pyrrolotriazine derivatives useful as TAM inhibitors |
| EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| AU2018371114A1 (en) | 2017-11-21 | 2020-05-07 | Innate Pharma | Multispecific antigen binding proteins |
| JP2021503885A (ja) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| AU2018380979B2 (en) | 2017-12-08 | 2023-07-20 | argenx BV | Use of FcRn antagonists for treatment of generalized myasthenia gravis |
| EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
| JP7565795B2 (ja) | 2017-12-15 | 2024-10-11 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法 |
| EP3731867A4 (en) | 2017-12-19 | 2022-04-06 | Surrozen Operating, Inc. | Anti-lrp5/6 antibodies and methods of use |
| EP3732201A4 (en) | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | WNT SURROGATES AND THEIR USES |
| US12006368B2 (en) | 2017-12-19 | 2024-06-11 | Surrozen Operating, Inc. | Anti-frizzled antibodies and methods of use |
| WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
| WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
| FR3076294B1 (fr) | 2017-12-29 | 2022-01-28 | Lab Francais Du Fractionnement | Procede de purification d'anticorps a partir de lait brut |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| KR102720600B1 (ko) * | 2018-01-10 | 2024-10-21 | 데날리 테라퓨틱스 인크. | 트랜스페린 수용체-결합 폴리펩타이드 및 이의 용도 |
| WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| US11078283B2 (en) | 2018-01-17 | 2021-08-03 | Apexigen, Inc. | Anti-PD-L1 antibodies and methods of use |
| CN111918674A (zh) | 2018-02-01 | 2020-11-10 | 比奥维拉迪维治疗股份有限公司 | 表达因子viii的慢病毒载体的用途 |
| MA51875A (fr) | 2018-02-13 | 2020-12-23 | Iovance Biotherapeutics Inc | Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine |
| CA3092470A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| WO2019169229A1 (en) | 2018-03-01 | 2019-09-06 | Nextcure, Inc. | Klrg1 binding compositions and methods of use thereof |
| EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR102874694B1 (ko) | 2018-03-21 | 2025-10-23 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| TW202003565A (zh) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 抗mica及/或micb抗體及其用途 |
| BR112020018709A2 (pt) | 2018-03-28 | 2021-01-05 | Bristol-Myers Squibb Company | Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso |
| EP3777888A4 (en) | 2018-03-30 | 2021-12-01 | Toray Industries, Inc. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER |
| CA3092387A1 (en) | 2018-04-02 | 2019-10-10 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
| EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| MA52289A (fr) | 2018-04-18 | 2021-02-24 | Xencor Inc | Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations |
| JP7402541B2 (ja) | 2018-05-03 | 2023-12-21 | ユニバーシティ オブ ロチェスター | 抗インフルエンザノイラミニダーゼモノクローナル抗体およびその使用 |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| LT3793588T (lt) | 2018-05-18 | 2025-06-25 | Bioverativ Therapeutics Inc. | Hemofilijos a gydymo būdai |
| CN112566938B (zh) | 2018-06-03 | 2025-04-01 | 拉姆卡普生物测试有限公司 | 针对ceacam5和cd47的双特异性抗体 |
| KR102848349B1 (ko) | 2018-06-04 | 2025-08-21 | 바이오젠 엠에이 인코포레이티드 | 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체 |
| MA52783A (fr) | 2018-06-05 | 2021-04-14 | Amgen Inc | Modulation de la phagocytose cellulaire dépendant de l'anticorps |
| BR112020025001A2 (pt) | 2018-06-08 | 2021-03-23 | Argenx Bvba | composições e métodos para o tratamento da trombocitopenia imune |
| US11830582B2 (en) | 2018-06-14 | 2023-11-28 | University Of Miami | Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents |
| IL279455B1 (en) | 2018-06-20 | 2025-09-01 | Incyte Corp | ANTI-PD-1 ANTIBODIES AND THEIR USES |
| ES3031110T3 (en) | 2018-06-29 | 2025-07-04 | Incyte Corp | Formulations of an axl/mer inhibitor |
| BR112020026512A2 (pt) | 2018-07-03 | 2021-04-06 | Bristol-Myers Squibb Company | Formulações de fgf-21 |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AU2019297361B2 (en) | 2018-07-05 | 2024-06-27 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
| DK3820906T3 (da) | 2018-07-05 | 2025-12-15 | Surrozen Operating Inc | Multispecifikke wnt-surrogatmolekyler og anvendelser deraf |
| EP3820904A2 (en) | 2018-07-09 | 2021-05-19 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| CN121203021A (zh) | 2018-07-11 | 2025-12-26 | 戊瑞治疗有限公司 | 在酸性pH下结合至VISTA的抗体 |
| JP7602454B2 (ja) | 2018-08-09 | 2024-12-18 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
| JP7523349B2 (ja) * | 2018-08-29 | 2024-07-26 | 中外製薬株式会社 | 抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法 |
| TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療 |
| FI3844189T3 (fi) | 2018-08-31 | 2025-03-05 | Regeneron Pharma | Annostusstrategia, joka lieventää bispesifisten CD3/CD20-vasta-aineiden sytokiinien vapautumisoireyhtymää |
| AU2019339895A1 (en) | 2018-09-11 | 2021-03-11 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113164780A (zh) | 2018-10-10 | 2021-07-23 | 泰洛斯治疗公司 | 抗lap抗体变体及其用途 |
| CR20210239A (es) | 2018-10-12 | 2021-12-15 | Xencor Inc | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas |
| WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
| ES3021682T3 (en) | 2018-11-05 | 2025-05-27 | Iovance Biotherapeutics Inc | Tumour infiltrating lymphocytes for use in treating nsclc patients refractory to anti-pd-1 antibodies |
| EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
| US12422441B2 (en) | 2018-12-07 | 2025-09-23 | Georgia Tech Research Corporation | Antibodies that bind to natively folded myocilin |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| WO2020132646A1 (en) | 2018-12-20 | 2020-06-25 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| CA3124352A1 (en) | 2019-01-04 | 2020-07-09 | Resolve Therapeutics, Llc | Treatment of sjogren's disease with nuclease fusion proteins |
| WO2020152081A1 (en) | 2019-01-22 | 2020-07-30 | Innate Pharma | Treatment of t cell lymphoma |
| CN113396162B (zh) | 2019-01-22 | 2024-08-16 | 百时美施贵宝公司 | 抗IL-7Rα亚基的抗体及其用途 |
| CA3127520A1 (en) | 2019-01-23 | 2020-07-30 | Encefa | Cd31 competitors and uses thereof |
| JP2022518814A (ja) | 2019-01-28 | 2022-03-16 | コーバー、インコーポレイテッド | 治療用ペプチド |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN113645996B (zh) | 2019-02-01 | 2024-04-02 | 新石生物制药有限公司 | 抗claudin 18抗体及其使用方法 |
| CA3130628A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| AU2020224154B2 (en) | 2019-02-21 | 2025-05-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| SG11202108955QA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Antibody molecules that bind to nkp30 and uses thereof |
| BR112021016875A2 (pt) | 2019-03-01 | 2022-01-04 | Iovance Biotherapeutics Inc | Processo para expansão de linfócitos de sangue periférico |
| CN113939534B (zh) | 2019-04-03 | 2025-02-28 | 建新公司 | 具有降低的断裂的抗αβTCR结合多肽 |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| CN114126647A (zh) | 2019-06-07 | 2022-03-01 | 阿尔金克斯有限公司 | 适用于皮下施用的FcRn抑制剂的药物制剂 |
| CA3143584A1 (en) | 2019-06-18 | 2020-12-24 | Bayer Aktiengesellschaft | Adrenomedullin-analogues for long-term stabilization and their use |
| CN114174536A (zh) | 2019-07-15 | 2022-03-11 | 百时美施贵宝公司 | 抗trem-1抗体及其用途 |
| JP2022540904A (ja) | 2019-07-15 | 2022-09-20 | ブリストル－マイヤーズ スクイブ カンパニー | ヒトｔｒｅｍ－１に対する抗体およびその使用 |
| CN114502196A (zh) | 2019-08-01 | 2022-05-13 | 因赛特公司 | Ido抑制剂的给药方案 |
| EP4031575A1 (en) | 2019-09-19 | 2022-07-27 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| US12403164B2 (en) | 2019-09-30 | 2025-09-02 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
| EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
| EP4085060A1 (en) | 2020-01-03 | 2022-11-09 | Incyte Corporation | Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| TW202140552A (zh) | 2020-01-08 | 2021-11-01 | 比利時商阿根思公司 | 用於治療天皰瘡病症的方法 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| WO2021146383A1 (en) | 2020-01-17 | 2021-07-22 | BioLegend, Inc. | Anti-tlr7 agents and compositions and methods for making and using the same |
| JP2023514152A (ja) | 2020-02-06 | 2023-04-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｌ－１０およびその使用 |
| CA3169521A1 (en) | 2020-02-28 | 2021-09-02 | Marie-Priscille Brun | Modified binding polypeptides for optimized drug conjugation |
| AU2021230385A1 (en) | 2020-03-06 | 2022-09-22 | Incyte Corporation | Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors |
| CA3175137A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| BR112022018163A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
| WO2021182571A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CA3175279A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3175129A1 (en) | 2020-03-12 | 2021-09-19 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| US20230107644A1 (en) | 2020-04-01 | 2023-04-06 | University Of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
| TWI884247B (zh) | 2020-04-01 | 2025-05-21 | 日商協和麒麟股份有限公司 | 抗體組合物 |
| EP4132971A1 (en) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinity matured anti-lap antibodies and uses thereof |
| KR20230028242A (ko) | 2020-04-24 | 2023-02-28 | 마렝고 테라퓨틱스, 인크. | T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도 |
| TW202216757A (zh) | 2020-04-28 | 2022-05-01 | 美國洛克菲勒大學 | 中和性抗ｓａｒｓ－ｃｏｖ－２抗體及其使用方法 |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| BR112022026127A2 (pt) | 2020-06-24 | 2023-01-17 | Bioverativ Therapeutics Inc | Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína |
| CA3165342A1 (en) | 2020-06-29 | 2022-01-06 | James Arthur Posada | Treatment of sjogren's syndrome with nuclease fusion proteins |
| WO2022047046A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Methods of detecting trbc1 or trbc2 |
| CN116917316A (zh) | 2020-08-26 | 2023-10-20 | 马伦戈治疗公司 | 与NKp30结合的抗体分子及其用途 |
| CN116249718A (zh) | 2020-08-26 | 2023-06-09 | 马伦戈治疗公司 | 结合至钙网蛋白的多功能性分子及其用途 |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022093641A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2a agents and compositions and methods for making and using the same |
| WO2022093640A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2c agents and compositions and methods for making and using the same |
| TW202227481A (zh) | 2020-11-04 | 2022-07-16 | 美國洛克菲勒大學 | 中和抗sars-cov-2抗體 |
| KR20230109668A (ko) | 2020-11-16 | 2023-07-20 | 서로젠 오퍼레이팅, 인크. | 간-특이적 Wnt 신호 증강 분자 및 그의 용도 |
| WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| CA3203587A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| JP2023551935A (ja) | 2020-12-02 | 2023-12-13 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｉｌ－７結合タンパク質および医学的療法におけるそれらの使用 |
| WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
| WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
| US20240299539A1 (en) | 2020-12-17 | 2024-09-12 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| US20240059763A1 (en) | 2020-12-18 | 2024-02-22 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory syncytial virus-specific binding molecule |
| HRP20240213T1 (hr) | 2020-12-18 | 2024-04-26 | Lamkap Bio Beta Ag | Bispecifična antitijela protiv ceacam5 i cd47 |
| AU2021411952A1 (en) | 2020-12-29 | 2023-08-10 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
| CA3203382A1 (en) | 2020-12-31 | 2022-07-07 | Adrian Emanual Wells | Devices and processes for automated production of tumor infiltrating lymphocytes |
| JP2024502863A (ja) | 2021-01-13 | 2024-01-23 | ビステラ， インコーポレイテッド | ヒト化補体５ａ受容体１抗体及びその使用方法 |
| EP4277926A1 (en) | 2021-01-15 | 2023-11-22 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
| EP4284919A1 (en) | 2021-01-29 | 2023-12-06 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| WO2022165434A2 (en) * | 2021-02-01 | 2022-08-04 | The General Hospital Corporation | Fc-enhanced antibodies for prevention and treatment of ebola virus infection |
| CN117279506A (zh) | 2021-03-05 | 2023-12-22 | 艾欧凡斯生物治疗公司 | 肿瘤储存及细胞培养组合物 |
| TW202304480A (zh) | 2021-03-19 | 2023-02-01 | 美商艾歐凡斯生物治療公司 | 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法 |
| CN118019546A (zh) | 2021-03-23 | 2024-05-10 | 艾欧凡斯生物治疗公司 | 肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途 |
| JP2024512029A (ja) | 2021-03-25 | 2024-03-18 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用 |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| EP4320147A4 (en) | 2021-04-08 | 2025-06-18 | Marengo Therapeutics, Inc. | TCR-BINDING MULTIFUNCTIONAL MOLECULES AND USES THEREOF |
| JP2024515189A (ja) | 2021-04-19 | 2024-04-05 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用 |
| EP4326271A1 (en) | 2021-04-23 | 2024-02-28 | F. Hoffmann-La Roche AG | Prevention or mitigation of nk cell engaging agent-related adverse effects |
| EP4334343A2 (en) | 2021-05-06 | 2024-03-13 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
| JP2024519029A (ja) | 2021-05-17 | 2024-05-08 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用 |
| WO2022248870A1 (en) | 2021-05-28 | 2022-12-01 | Glaxosmithkline Intellectual Property Development Limited | Combination therapies for treating cancer |
| CN113322223B (zh) * | 2021-06-03 | 2023-09-12 | 重庆市畜牧科学院 | 富硒酵母基因工程菌及其表面展示系统及其构建方法 |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| MX2023014645A (es) | 2021-06-09 | 2024-01-31 | Innate Pharma | Proteinas acopladoras de celulas nk de union a nkp46 especificas de cd20. |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| US20240325529A1 (en) | 2021-06-23 | 2024-10-03 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2022270524A1 (ja) | 2021-06-23 | 2022-12-29 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| US12448451B2 (en) | 2021-06-25 | 2025-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
| US20240365776A1 (en) | 2021-07-22 | 2024-11-07 | Iovance Biotherapeutics, Inc | Method for cryopreservation of solid tumor fragments |
| US20250325663A1 (en) | 2021-07-27 | 2025-10-23 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2023010060A2 (en) | 2021-07-27 | 2023-02-02 | Novab, Inc. | Engineered vlrb antibodies with immune effector functions |
| US20250281607A1 (en) | 2021-07-27 | 2025-09-11 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| US20250066502A1 (en) | 2021-07-27 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| US12467921B2 (en) | 2021-08-31 | 2025-11-11 | Versitech Limited | Antibodies and assays for detection of Burkholderia mallei |
| AU2022338463A1 (en) | 2021-09-03 | 2024-03-21 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| KR20240109615A (ko) | 2021-09-09 | 2024-07-11 | 이오반스 바이오테라퓨틱스, 인크. | Pd-1 talen 녹다운을 사용한 til 생성물의 생성 방법 |
| EP4404969A1 (en) | 2021-09-24 | 2024-07-31 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| CN118159294A (zh) | 2021-10-05 | 2024-06-07 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于治疗癌症的联合疗法 |
| JP2024541911A (ja) | 2021-10-27 | 2024-11-13 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 患者特異的免疫療法のための細胞の製造を調整するためのシステム及び方法 |
| CA3237410A1 (en) | 2021-11-10 | 2023-05-19 | Friedrich Graf Finck VON FINCKENSTEIN | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| KR20240131370A (ko) | 2021-12-22 | 2024-08-30 | 인사이트 코포레이션 | 항-cd19 항체 요법을 위한 치료 패러다임 |
| EP4466070A1 (en) | 2022-01-18 | 2024-11-27 | argenx BV | Galectin-10 antibodies |
| WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
| CA3243419A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | CYTOKINE-ASSOCIATED TUMOR-INFILTRATING LYMPHOCYTE COMPOSITIONS AND PROCESSES |
| EP4469066A1 (en) | 2022-01-28 | 2024-12-04 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
| IL314524A (en) | 2022-01-28 | 2024-09-01 | Georgiamune Inc | Antibodies to programmed cell death protein 1 that are agonists for PD-1 |
| WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| EP4507704A1 (en) | 2022-04-15 | 2025-02-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| CA3251533A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST |
| TW202413441A (zh) | 2022-05-27 | 2024-04-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | TNF-α結合蛋白及IL-7結合蛋白於醫藥治療之用途 |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| AU2023291783A1 (en) | 2022-06-15 | 2024-12-12 | argenx BV | Fcrn binding molecules and methods of use |
| US20250230256A1 (en) | 2022-06-16 | 2025-07-17 | Lamkap Bio Beta Ltd | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
| AU2023298568A1 (en) | 2022-06-30 | 2025-01-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| EP4551681A1 (en) | 2022-07-06 | 2025-05-14 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
| EP4558523A1 (en) | 2022-07-19 | 2025-05-28 | Biolegend, Inc. | Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same |
| KR20250040994A (ko) | 2022-07-22 | 2025-03-25 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 pad4에 결합하는 항체 및 그의 용도 |
| WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| EP4572854A2 (en) | 2022-08-18 | 2025-06-25 | Biolegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
| CN119744176A (zh) | 2022-08-24 | 2025-04-01 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| JPWO2024043252A1 (enExample) | 2022-08-24 | 2024-02-29 | ||
| CN119768181A (zh) | 2022-08-24 | 2025-04-04 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| JPWO2024048541A1 (enExample) | 2022-08-30 | 2024-03-07 | ||
| KR20250054778A (ko) | 2022-08-30 | 2025-04-23 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| JP2025529210A (ja) | 2022-09-01 | 2025-09-04 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法 |
| WO2024062082A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| KR20250060305A (ko) | 2022-09-21 | 2025-05-07 | 사노피 바이오테크놀로지 | 인간화 항-il-1r3 항체 및 사용 방법 |
| WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| TW202421193A (zh) | 2022-09-28 | 2024-06-01 | 美商英塞特公司 | 抗ｐｄ－１／ｌａｇ－３雙特異性抗體及其用途 |
| EP4608859A1 (en) | 2022-10-25 | 2025-09-03 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
| AU2023367781A1 (en) | 2022-10-25 | 2025-06-05 | Seismic Therapeutic, Inc. | VARIANT IgG FC POLYPEPTIDES AND USES THEREOF |
| WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| EP4612277A1 (en) | 2022-11-04 | 2025-09-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
| US20240190978A1 (en) | 2022-11-15 | 2024-06-13 | CSBioAsset LLC | Compositions and methods for immunomodulatory bifunctional fusion molecules |
| EP4623072A2 (en) | 2022-11-21 | 2025-10-01 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
| WO2024112711A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Methods for assessing proliferation potency of gene-edited t cells |
| CN120302998A (zh) | 2022-12-23 | 2025-07-11 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
| WO2024186635A2 (en) | 2023-03-03 | 2024-09-12 | Celldex Therapeutics, Inc. | Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| AU2024251960A1 (en) | 2023-04-14 | 2025-10-23 | Incyte Corporation | Use of an anti-tgfbetar2/pd-1 bispecific antibody to treat cancer |
| CN121219009A (zh) | 2023-05-17 | 2025-12-26 | 信达克思制药公司 | 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病相关的闭塞性细支气管炎综合征的方法 |
| CN121152803A (zh) | 2023-05-25 | 2025-12-16 | 百进公司 | Ceacam6结合抗体和其抗原结合片段 |
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
| WO2024251884A1 (en) | 2023-06-09 | 2024-12-12 | Innate Pharma | Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| TW202509219A (zh) | 2023-07-13 | 2025-03-01 | 美商艾歐凡斯生物治療公司 | 編碼細胞介素之慢病毒載體及其用於製備腫瘤浸潤性淋巴球之用途 |
| WO2025019790A1 (en) | 2023-07-19 | 2025-01-23 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
| WO2025024265A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad4 modulators |
| WO2025024272A1 (en) | 2023-07-23 | 2025-01-30 | Incyte Corporation | Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody |
| TW202525845A (zh) | 2023-08-23 | 2025-07-01 | 法商賽諾菲公司 | 基於ｃｔｌａ—４之溶體降解劑及其用途 |
| EP4590715A1 (en) | 2023-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025061993A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| US20250109187A1 (en) | 2023-09-28 | 2025-04-03 | Novavax, Inc. | ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19 |
| WO2025085489A1 (en) | 2023-10-17 | 2025-04-24 | Bristol-Myers Squibb Company | Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof |
| US20250154262A1 (en) * | 2023-10-25 | 2025-05-15 | Ablynx N.V. | Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
| US20250186450A1 (en) | 2023-12-06 | 2025-06-12 | Incyte Corporation | COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS |
| WO2025133694A1 (en) | 2023-12-20 | 2025-06-26 | argenx BV | Fcrn/hsa-binding molecules and methods of use |
| GB202319605D0 (en) | 2023-12-20 | 2024-01-31 | argenx BV | Monovalent binding molecules and methods of use |
| WO2025155877A2 (en) | 2024-01-18 | 2025-07-24 | The Regents Of The University Of California | Antibodies binding to pad4 and uses thereof |
| WO2025171182A1 (en) | 2024-02-08 | 2025-08-14 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine |
| WO2025174974A1 (en) | 2024-02-14 | 2025-08-21 | Bristol-Myers Squibb Company | Anti-cd33 antibodies and uses thereof |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| EP4658320A1 (en) | 2024-02-27 | 2025-12-10 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025226637A1 (en) | 2024-04-22 | 2025-10-30 | Incyte Corporation | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor |
| EP4653010A1 (en) | 2024-05-14 | 2025-11-26 | 35Pharma Inc. | Activin receptor type iib traps for use in improving body composition |
| WO2025245176A1 (en) | 2024-05-22 | 2025-11-27 | Bristol-Myers Squibb Company | Multispecific antibody constructs |
| WO2025255349A1 (en) | 2024-06-06 | 2025-12-11 | Bristol-Myers Squibb Company | Multispecific anti-cd40 / anti-fap antibodies and uses thereof |
| WO2025255405A1 (en) | 2024-06-06 | 2025-12-11 | Bristol-Myers Squibb Company | Anti-fap antibodies and uses thereof |
Family Cites Families (200)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4347935A (en) | 1979-05-16 | 1982-09-07 | The United States Of America As Represented By The United States Department Of Energy | Method and apparatus for electrostatically sorting biological cells |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4752601A (en) * | 1983-08-12 | 1988-06-21 | Immunetech Pharmaceuticals | Method of blocking immune complex binding to immunoglobulin FC receptors |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5985599A (en) * | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| AU600575B2 (en) * | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| FR2626882B1 (fr) | 1988-02-08 | 1991-11-08 | Ire Celltarg Sa | Conjugues de derives de vinca comportant une chaine detergente en position c-3 |
| US4861579A (en) | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
| EP0791653B9 (en) | 1988-05-27 | 2006-08-30 | Applied Research Systems ARS Holding N.V. | Human Fc-gamma receptor III |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5576184A (en) * | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
| ATE159982T1 (de) | 1988-09-15 | 1997-11-15 | Univ Columbia | Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| GB8916400D0 (en) * | 1989-07-18 | 1989-09-06 | Dynal As | Modified igg3 |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| FI85768C (fi) | 1990-07-04 | 1992-05-25 | Valtion Teknillinen | Foerfarande foer utfoerning av ytplasmonresonansmaetning samt i foerfarandet anvaendbar givare. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992006180A1 (en) | 1990-10-01 | 1992-04-16 | University Of Connecticut | Targeting viruses and cells for selective internalization by cells |
| CA2093022C (en) | 1990-10-05 | 2005-02-22 | Michael W. Fanger | Targeted immunostimulation with bispecific reagents |
| US5364930A (en) * | 1990-10-16 | 1994-11-15 | Northwestern University | Synthetic C1q peptide fragments |
| DE69128253T2 (de) | 1990-10-29 | 1998-06-18 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
| GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
| AU665758B2 (en) | 1991-04-26 | 1996-01-18 | Surface Active Limited | Novel antibodies, and methods for their use |
| AU666852B2 (en) | 1991-05-01 | 1996-02-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
| EP0584279B1 (en) | 1991-05-14 | 2001-03-14 | The University Of Connecticut | Targeted delivery of genes encoding immunogenic proteins |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1992022635A1 (en) | 1991-06-05 | 1992-12-23 | University Of Connecticut | Targeted delivery of genes encoding secretory proteins |
| DE69110032T2 (de) | 1991-06-08 | 1995-12-21 | Hewlett Packard Gmbh | Verfahren und Gerät zur Feststellung und/oder Konzentrationsbestimmung von Biomolekülen. |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5223408A (en) * | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
| DE69332948T2 (de) | 1992-03-05 | 2003-11-27 | Board Of Regents, The University Of Texas System | Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| CA2133411A1 (en) | 1992-04-03 | 1993-10-14 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| PL171749B1 (pl) | 1992-06-09 | 1997-06-30 | Hoppe Ag | Zamek zatrzaskowypopychacz , wspólpracujacy z lukowym wglebie- PL PL PL PL |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE200625T1 (de) | 1992-10-09 | 2001-05-15 | Advanced Tissue Sciences Inc | Leberreservezellen |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| EP1262564A3 (en) | 1993-01-07 | 2004-03-31 | Sequenom, Inc. | Dna sequencing by mass spectrometry |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6114147A (en) | 1993-02-10 | 2000-09-05 | Unilever Patent Holdings | Immobilized proteins with specific binding capacities and their use in processes and products |
| US5877396A (en) | 1993-04-23 | 1999-03-02 | Sloan Kettering Institute For Cancer Research | Mice mutant for functional Fc receptors and method of treating autoimmune diseases |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| EP0711303B2 (en) * | 1993-07-30 | 2009-06-10 | Affymax, Inc. | Biotinylation of proteins |
| US5464581A (en) | 1993-08-02 | 1995-11-07 | The Regents Of The University Of California | Flow cytometer |
| US5483469A (en) | 1993-08-02 | 1996-01-09 | The Regents Of The University Of California | Multiple sort flow cytometer |
| GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
| ATE214940T1 (de) | 1993-11-10 | 2002-04-15 | Enzon Inc | Verbesserte interferon-polymerkonjugate |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US5602039A (en) | 1994-10-14 | 1997-02-11 | The University Of Washington | Flow cytometer jet monitor system |
| US5643796A (en) | 1994-10-14 | 1997-07-01 | University Of Washington | System for sensing droplet formation time delay in a flow cytometer |
| JPH10511957A (ja) | 1995-01-05 | 1998-11-17 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン | 表面改質ナノ微粒子並びにその製造及び使用方法 |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5916597A (en) | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US5942328A (en) | 1996-02-29 | 1999-08-24 | International Business Machines Corporation | Low dielectric constant amorphous fluorinated carbon and method of preparation |
| JP2000506165A (ja) | 1996-03-04 | 2000-05-23 | ザ ペン ステイト リサーチ ファウンデーション | 細胞インターナリゼーションを増強するための物質および方法 |
| WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| EP0904278A4 (en) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | MOLECULE II INDUCER OF APOPTOSIS |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6699658B1 (en) * | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6300065B1 (en) * | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| ATE386809T1 (de) | 1996-08-02 | 2008-03-15 | Bristol Myers Squibb Co | Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6025485A (en) * | 1997-02-14 | 2000-02-15 | Arcaris, Inc. | Methods and compositions for peptide libraries displayed on light-emitting scaffolds |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6339069B1 (en) | 1996-10-15 | 2002-01-15 | Elan Pharmaceuticalstechnologies, Inc. | Peptide-lipid conjugates, liposomes and lipsomal drug delivery |
| GB9623820D0 (en) | 1996-11-16 | 1997-01-08 | Secr Defence | Surface plasma resonance sensor |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| PT954282E (pt) | 1997-01-16 | 2005-06-30 | Massachusetts Inst Technology | Preparacao de particulas para inalacao |
| ATE427966T1 (de) | 1997-02-11 | 2009-04-15 | Immunomedics Inc | Stimulation einer immunantwort durch antikírper, welche mit dem alpha-galaktosylepitop markiert sind |
| US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| AU4754397A (en) | 1997-10-15 | 1999-05-03 | Medarex, Inc. | Bispecific molecules directed to tumor associated glycoprotein-72 and fc receptor |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| CA2248971A1 (en) | 1997-10-31 | 1999-04-30 | Kyowa Hakko Kogyo Co., Ltd. | .beta.1, 3-n-acetylglucosaminyltransferase, dna encoding it and its use |
| CN1174993C (zh) | 1997-11-03 | 2004-11-10 | 人体基因组科学有限公司 | Vegi,一种血管发生和肿瘤生长的抑制剂 |
| KR20010041010A (ko) | 1998-02-17 | 2001-05-15 | 메다렉스, 인코포레이티드 | Ｆｃ 수용체 리간드를 사용하여 마크로파지 매개 질환을치료하고 진단하는 방법 |
| BR9908226A (pt) | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
| US6211477B1 (en) | 1998-02-26 | 2001-04-03 | Becton Dickinson And Company | Electrostatic deceleration system for flow cytometer |
| US6455263B2 (en) * | 1998-03-24 | 2002-09-24 | Rigel Pharmaceuticals, Inc. | Small molecule library screening using FACS |
| US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) * | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| EP1068241B1 (en) * | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
| EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP2002518663A (ja) | 1998-05-20 | 2002-06-25 | グラッフィニティ ファルマシューティカル デザイン ゲーエムベーハー | 液体状態で存在する多数の試料を同時に測定するためのｓｐｒセンサー |
| US6289286B1 (en) | 1998-05-29 | 2001-09-11 | Biacore Ab | Surface regeneration of biosensors and characterization of biomolecules associated therewith |
| WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
| JP3504166B2 (ja) * | 1998-11-25 | 2004-03-08 | 株式会社新川 | フリップチップボンディング装置 |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209786B1 (pl) * | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| EP2264072A1 (en) | 2000-04-13 | 2010-12-22 | The Rockefeller University | Enhancement of antibody-mediated cytotoxicity. |
| EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US20030199671A1 (en) | 2001-04-18 | 2003-10-23 | Rondon Isaac Jesus | Binding molecules for Fc-region polypeptides |
| EP1385545B1 (en) | 2001-04-30 | 2009-01-07 | Eli Lilly And Company | Humanized antibodies recognizing the beta-amyloid peptide |
| US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
| EP2072059A1 (en) | 2001-10-12 | 2009-06-24 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| WO2003066095A2 (en) | 2002-02-07 | 2003-08-14 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING |
| US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| CA2494310A1 (en) | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| ATE536188T1 (de) * | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
| US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| US6930093B2 (en) * | 2003-07-10 | 2005-08-16 | Valeant Research & Development | Use of ribofuranose derivatives against inflammatory bowel diseases |
| WO2005018669A1 (en) | 2003-08-18 | 2005-03-03 | Macrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
| PL1706424T3 (pl) | 2004-01-12 | 2010-04-30 | Mentrik Biotech Llc | Warianty regionu Fc |
| WO2005115452A2 (en) | 2004-04-16 | 2005-12-08 | Macrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
| JP2007536932A (ja) | 2004-05-10 | 2007-12-20 | マクロジェニクス，インコーポレーテッド | ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| ZA200701234B (en) | 2004-07-22 | 2008-12-31 | Genentech Inc | HER2 antibody composition |
| AU2005274905B2 (en) | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| KR101247908B1 (ko) | 2004-09-02 | 2013-03-26 | 제넨테크, 인크. | 항-ｆｃ-감마 ｒｉｉｂ 수용체 항체 및 그의 용도 |
| US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| US7662926B2 (en) | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| EP1833849A4 (en) | 2004-12-15 | 2009-08-05 | Macrogenics Inc | FC-GAMMA-RIIB-SPECIFIC ANTIBODIES AND METHODS FOR THEIR USE |
| US9296816B2 (en) | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| ES2526811T3 (es) | 2005-08-10 | 2015-01-15 | Macrogenics, Inc. | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos |
| WO2007055916A2 (en) | 2005-11-07 | 2007-05-18 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| EP1999470A4 (en) | 2006-03-10 | 2009-08-19 | Macrogenics Inc | IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF |
| EP2021029B1 (en) | 2006-05-26 | 2014-06-11 | MacroGenics, Inc. | Humanized fc gamma riib-specific antibodies and methods of use thereof |
| EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| LT2029173T (lt) | 2006-06-26 | 2016-11-10 | Macrogenics, Inc. | Fc riib specifiniai antikūnai ir jų panaudojimo būdai |
| MX2008015830A (es) | 2006-06-30 | 2009-01-09 | Novo Nordisk As | Anticuerpos anti-nkg2a y usos de los mismos. |
| WO2009083009A2 (en) | 2008-01-03 | 2009-07-09 | Genmab A/S | Monoclonal antibodies against cd32b |
| MX2010010387A (es) | 2008-04-02 | 2010-10-15 | Macrogenics Inc | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. |
-
2004
- 2004-01-09 ES ES04701279T patent/ES2897506T3/es not_active Expired - Lifetime
- 2004-01-09 WO PCT/US2004/000643 patent/WO2004063351A2/en not_active Ceased
- 2004-01-09 US US10/754,922 patent/US7355008B2/en not_active Expired - Lifetime
- 2004-01-09 EP EP04701279.4A patent/EP1587540B1/en not_active Expired - Lifetime
- 2004-01-09 AU AU2004204494A patent/AU2004204494B2/en not_active Ceased
- 2004-01-09 EP EP10187696A patent/EP2368578A1/en not_active Withdrawn
- 2004-01-09 CA CA2512729A patent/CA2512729C/en not_active Expired - Lifetime
- 2004-01-09 JP JP2006500901A patent/JP2006524039A/ja active Pending
-
2005
- 2005-07-07 IL IL169603A patent/IL169603A/en active IP Right Grant
-
2008
- 2008-01-30 US US12/022,762 patent/US8003774B2/en not_active Expired - Lifetime
- 2008-01-30 US US12/022,772 patent/US8192737B2/en not_active Expired - Lifetime
-
2010
- 2010-12-28 JP JP2010292632A patent/JP2011121954A/ja active Pending
-
2011
- 2011-07-13 US US13/182,209 patent/US9028815B2/en not_active Expired - Lifetime
-
2014
- 2014-10-02 JP JP2014203774A patent/JP6389093B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-08 US US14/681,491 patent/US20150259396A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004063351A3 (en) | 2005-03-31 |
| JP2015044817A (ja) | 2015-03-12 |
| US20150259396A1 (en) | 2015-09-17 |
| IL169603A0 (en) | 2007-07-04 |
| US7355008B2 (en) | 2008-04-08 |
| AU2004204494B2 (en) | 2011-09-29 |
| WO2004063351A2 (en) | 2004-07-29 |
| JP2011121954A (ja) | 2011-06-23 |
| JP2006524039A (ja) | 2006-10-26 |
| EP1587540B1 (en) | 2021-09-15 |
| US9028815B2 (en) | 2015-05-12 |
| CA2512729A1 (en) | 2004-07-29 |
| EP1587540A4 (en) | 2008-09-10 |
| US8003774B2 (en) | 2011-08-23 |
| AU2004204494A1 (en) | 2004-07-29 |
| JP6389093B2 (ja) | 2018-09-12 |
| US8192737B2 (en) | 2012-06-05 |
| US20080138344A1 (en) | 2008-06-12 |
| US20080131435A1 (en) | 2008-06-05 |
| ES2897506T3 (es) | 2022-03-01 |
| IL169603A (en) | 2016-08-31 |
| EP2368578A1 (en) | 2011-09-28 |
| US20110305714A1 (en) | 2011-12-15 |
| EP1587540A2 (en) | 2005-10-26 |
| US20050037000A1 (en) | 2005-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2512729C (en) | Identification and engineering of antibodies with variant fc regions and methods of using same | |
| KR101357813B1 (ko) | 변이체 ｆｃ 영역을 가진 항체의 확인 및 조작 및 이것의사용 방법 | |
| CA2776385C (en) | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use | |
| CA2618681C (en) | Identification and engineering of antibodies with variant fc regions and methods of using same | |
| CN110997712B (zh) | 特异性结合pd-1的抗体及其使用方法 | |
| AU2005335714B2 (en) | Engineering Fc antibody regions to confer effector function | |
| EP3692065A1 (en) | Igg1 fc mutants with ablated effector functions | |
| JP2009529331A (ja) | 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法 | |
| WO2008140603A2 (en) | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING | |
| AU2011265460B2 (en) | Identification and engineering of antibodies with variant Fc regions and methods of using same | |
| CN101189028B (zh) | 具有变异Fc区的抗体的鉴定和工程化以及使用方法 | |
| HK1085911A (en) | Identification and engineering of antibodies with variant fc regions and methods of using same | |
| HK1085911B (en) | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME | |
| HK1162325A (en) | Identification and engineering of antibodies with variant fc regions and methods of using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20240109 |